The aim of this study was to evaluate the consequences of interleukin (IL)-4-induced 15-lipoxygenase (15-LO) expression on leukotriene B4 (LTB4) synthesis in human monocytes. Human monocytes incubated for 24, 48, and 72 h with IL-4 (10 ng/ml) were stimulated with Ca2+-ionophore A23187 (calcimycin; 5 microM) or opsonized zymosan. 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE], LTB4, and arachidonic acid (AA) release were measured by high-performance liquid chromatography/radioimmunoassay, liquid chromatography/tandem mass spectrometry (LC/MS/MS), or gas chromatography/mass spectrometry. 15-LO activity was evaluated in AA-treated monocytes. 15-LO, 5-lipoxygenase (5-LO) and 5-LO activating protein (FLAP) expression were analyzed by reverse transcription-polymerase chain reaction. Neutrophil chemotactic activity was evaluated using a microtaxis chamber assay. A23187-induced synthesis of 15(S)-HETE was significantly increased after treatment with IL-4 (10 ng/ml) for 48 and 72 h (p < 0.001). Concomitant decrease of LTB4 release was observed after 72 h of incubation with IL-4 (p < 0.001). LC/MS/MS analysis confirmed the production of 15(S)-HETE and the significant inhibition of LTB4 synthesis in IL-4-treated monocyte after challenge with opsonized zymosan. IL-4 treatment induced 15-LO enzymatic activity as well as 15-LO mRNA, but did not affect either 5-LO or FLAP mRNA expression in monocytes. Supernatant from IL-4-treated monocytes showed significantly lower neutrophil chemotactic activity than controls. 15(S)-HETE significantly inhibited LTB4 production induced by A23187-stimulated human monocytes without affecting AA release. IL-4-induced expression of 15-LO in monocytes caused a significant reduction of LTB4 production. Whereas this effect did not reflect changes in 5-LO and FLAP mRNA expression, synthetic 15(S)-HETE was able to significantly inhibit the synthesis of LTB4, without affecting AA release.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1124/jpet.300.3.868 | DOI Listing |
Alzheimers Dement
December 2024
Wake Forest Alzheimer's Disease Research Center, Winston-Salem, NC, USA.
Background: Diet composition is associated with neurodegenerative disease risk including Alzheimer's Disease (AD). The adverse effects of Western-style diets may be moderated, in part, by systemic as well as central inflammation, whereas the neuroprotective effects of Mediterranean diets may work through mechanisms that promote anti-inflammatory phenotypes. Systemic inflammation also may induce insulin resistance, another risk factor for AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Department of Psychiatry, University of Cambridge, Cambridge, UK.
Background: Combinations of blood-based biomarkers have been used to detect Alzheimer's disease (AD). While these markers provide information about neuropathology, they fail to integrate the cellular dysfunction, such as disease-associated defects in lysosomal ion homeostasis. To understand cellular dysfunction in AD and its relation to the pathophysiology of the disease, we developed a multi-modal biomarker diagnostic platform that incorporates lysosomal ionic pH and Ca and plasma levels of Amyloid beta (Aβ), Amyloid beta (Aβ), phosphorylated Tau181 (pTau181), Neurofilament light (NfL) and Glial fibrillary acidic protein (GFAP).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Florida College of Medicine, Gainesville, FL, USA.
Background: Peripheral blood mononuclear cells (PBMCs) were obtained from patients across different stages of Parkinson's disease (PD) progression and stimulated ex vivo to develop biomarkers for predicting PD progression.
Method: PBMCs obtained at one time-point from patients with moderate stage PD (>5 years after diagnosis) (n = 30), early stage PD (<5 years after diagnosis) (n = 27), prodromal PD (rapid-eye-movement sleep behavior disorder patients) (n = 14), and healthy controls (HCs) (n = 9) were isolated from whole blood and cryopreserved. Samples were thawed, then pan-monocytes and T-cell populations were isolated from PBMCs and subjected to treatment with vehicle or IFN-γ.
Background: Alzheimer's disease (AD) patients have decline in cognitive domains including memory, language, visuospatial, and/or executive function and brain pathology including amyloid-β and tau deposition, neurodegeneration, and frequent vascular co-pathologies detectable by neuroimaging and/or cerebrospinal fluid biomarkers. However, molecular disease mechanisms are complex and heterogeneous. It is necessary to develop cost-effective blood-based biomarkers reflecting brain molecular perturbations in AD.
View Article and Find Full Text PDFBackground: The microbiota-immune-brain axis is implicated in Alzheimer's disease. Alterations in gut microbiota and immune functions in mild cognitive impairment (MCI) are inconsistent and remain to be understood. This study aims to investigate immune cell phenotyping and its link with gut microbial composition associated with cognitive function.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!